Abstract
Introduction. Suppression of activation of an alternative immune response is promising approach of tumor immunotherapy. In this study we evaluated antitumor and antimetastatic activity of SNK-411.Objective. Evaluation of antitumor and antimetastatic activity of 5-hydroxypyrimidine derivative SNK-411 in mouse melanoma B16 model.Materials and methods. Antitumor and antimetastatic activity of the SNK-411 were studied in tests on male C57BL/6 mice using the B16-F10 melanoma model. SNK-411 was injected intraperitoneally at doses of 10 and 25 mg/kg from day 2 to day 15 of melanoma development. Doxorubicin was injected at dose of 4 mg/kg on day 2 of tumor development to act as positive control. Antitumor and antimetastatic activity were studied by calculation of tumor growth inhibition and metastasis inhibition index (MII).Results. SNK-411 at doses of 10 and 25 mg/kg and in combination with single injection of doxorubicin in dose of 4 mg/kg showed antimetastatic activity. MII in SNK-411 at 10 mg/kg dose was 72 %, at dose of 25 mg/kg was 82,9 %. The combination of 14-day course of intraperitoneal injections of SNK-411 at dose of 10 mg/kg and injection of doxorubicin 4 mg/kg revealed MII 97,1 %, in half of mice in this group metastasis were not observed on 21st day of melanoma development. All results are statistically significant. There was no significant inhibition of tumor growth in all groups.Conclusion. SNK-411 has antimetastatic activity in tests on melanoma B16 model. Further investigation is required.
Highlights
Suppression of activation of an alternative immune response is promising approach of tumor immunotherapy
In this study we evaluated antitumor and antimetastatic activity of SNK-411
Antitumor and antimetastatic activity of the SNK-411 were studied in tests on male C57BL / 6 mice using the B16‐F10 melanoma model
Summary
Suppression of activation of an alternative immune response is promising approach of tumor immunotherapy. Цель исследования – оценка противоопухолевой и антиметастатической активности производного 5‐оксипиримидина СНК-411 при его курсовом введении и в сочетании с однократным введением доксорубицина на модели меланомы B16. Результаты и обсуждение После окончания курсового введения СНК-411 в дозах 10 и 25 мг / кг и в сочетании с однократным введением доксорубицина статистически значимого ТРО на 21‐й день развития меланомы B16 в опытных группах не обнаружено Влияние СНК-411 на процесс метастазирования в легких мышей оценивали на 21‐е сутки после инокуляции меланомы B16 и эвтаназии животных. При применении комбинации 14‐дневного введения СНК-411 в дозе 10 мг / кг и однократного введения доксорубицина в дозе 4 мг / кг ИИМ составил 97,1 %, у половины мышей этой группы на 21‐й день развития меланомы B16 метастазы в легких не были выявлены. Влияние СНК-411 при внутрибрюшинном введении в разных дозах и совместно с однократным введением доксорубицина на рост меланомы В16
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
